Long-Term Safety Study of BCMACP03, BCN-CP01, and 19CP02 for Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, CLL, SLL, or Multiple Myeloma

This clinical trial is focused on studying the long-term safety of a treatment for certain types of blood cancers. The diseases being studied include Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), and Relapsed/Refractory Multiple Myeloma. The treatment involves a type of cell therapy known as CAR T-cell therapy, which uses the body's own immune cells, called T cells, that are modified to better fight cancer. The specific treatments being tested are called BCMACP03, BCN-CP01, and 19CP02. These treatments are given as an infusion, which means they are delivered directly into the bloodstream through a vein.

The purpose of this study is to evaluate the long-term safety of these CAR T-cell therapies for up to 15 years after the treatment is given. Participants in the study will be monitored over this period to check for any side effects or health changes. This includes looking at the type and frequency of any adverse events, which are unexpected medical problems that occur during treatment. The study will also track the presence of the CAR T-cells in the blood and any changes in the disease status, such as progression or the need for additional cancer treatments.

Throughout the study, researchers will collect information on overall survival and any new health issues that may arise. This information will help determine the long-term effects of the CAR T-cell therapies and their safety for patients who have received them. The study aims to provide valuable insights into how these treatments work over time and their impact on patients' health.